Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 232-237

  Delongchamps, N B ^a   Beuvon, F ^a   Eiss, D ^b   Flam, T ^a   Muradyan, N ^c   Zerbib, M ^a   Peyromaure, M ^a   Cornud, F ^a,b  

^a Paris Descartes University ^*  (France)

^b IRM Paris 16   (France)

^c ICAD INC   (United States)

Author keywords

Diffusion; dynamic contrast enhanced; low risk; MRI

Indexed keywords

GADOLINIUM;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER SIZE; CANCER STAGING; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE PROCESSING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

AGED; AREA UNDER CURVE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; STATISTICS, NONPARAMETRIC; TUMOR BURDEN;

EID: 80054729022     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.9     Document Type: Article

References (24)

1. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38: 74-78 (Pubitemid 30418019)
2. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374 (Pubitemid 24037911)
3. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-938
4. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-1322 (Pubitemid 47446019)
5. Giannarini G, Autorino R, di Lorenzo G. Saturation biopsy of the prostate: why saturation does not saturate. Eur Urol 2009; 56: 619-621
6. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009; 55: 801-814
7. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP et al. A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active Surveillance. Eur Urol 2009; 56: 981-987
8. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhancedMRI in prostate cancer. Eur J Radiol 2007; 63: 335-350 (Pubitemid 47321040)
9. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusionweighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-334
10. D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004; 22: 3726-3732 (Pubitemid 41095213)
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232 (Pubitemid 29463104)
12. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16: 167-172
13. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003; 27: 1291-1301 (Pubitemid 37185820)
14. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-2437 (Pubitemid 44665992)
15. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242 (Pubitemid 41232997)
16. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24: 108-113
17. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusionweighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152 (Pubitemid 46095209)
18. Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, Kraus S et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-888
19. Lemaitre L, Puech P, Poncelet E, Bouye S, Leroy X, Biserte J et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009; 19: 470-480
20. Cornud F, Beuvon F, Thevenin F, Chauveinc L, Vieillefond A, Descazeaux A et al. Quantitative dynamic MRI and localisation of non-palpable prostate cancer. Prog Urol 2009; 19: 401-413
21. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM et al. Prostate dynamic contrastenhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17: 1498-1509 (Pubitemid 46767598)
22. HaiderMA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi A-T, Lockwood G et al. Combined T2-Weighted and Diffusion- Weighted MRI for Localization of Prostate Cancer. Am J Roentgenol 2007; 189: 323-328 (Pubitemid 47195916)
23. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 2008; 49: 1207-1213
24. deSouza NM, Riches SF, Vanas NJ, Morgan VA, Ashley SA, Fisher C, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782.